Eli Lilly (LLY) Upside Source Removed After Alzheimer Trial Discontinuation, Reit $134 PT At BMO

March 21, 2019 9:28 AM
BMO Capital analyst Alex Arfaei reiterated an Outperform rating and $134.00 price target on Eli Lilly (NYSE: LLY) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments

Next Articles